JP2017006120A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017006120A5 JP2017006120A5 JP2016109398A JP2016109398A JP2017006120A5 JP 2017006120 A5 JP2017006120 A5 JP 2017006120A5 JP 2016109398 A JP2016109398 A JP 2016109398A JP 2016109398 A JP2016109398 A JP 2016109398A JP 2017006120 A5 JP2017006120 A5 JP 2017006120A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- molecule
- drb1
- cancer
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims 28
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 claims 8
- 108010045483 HLA-DPB1 antigen Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 claims 4
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 claims 4
- 108010061311 HLA-DRB3 Chains Proteins 0.000 claims 4
- 108010040960 HLA-DRB4 Chains Proteins 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000003115 germ cell cancer Diseases 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010225806 | 2010-10-05 | ||
| JP2010225806 | 2010-10-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537718A Division JP6134139B2 (ja) | 2010-10-05 | 2011-10-04 | ヘルパーｔ細胞の活性化方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017237964A Division JP2018093870A (ja) | 2010-10-05 | 2017-12-12 | ヘルパーｔ細胞の活性化方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017006120A JP2017006120A (ja) | 2017-01-12 |
| JP2017006120A5 true JP2017006120A5 (OSRAM) | 2017-05-25 |
| JP6298101B2 JP6298101B2 (ja) | 2018-03-20 |
Family
ID=45927725
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537718A Active JP6134139B2 (ja) | 2010-10-05 | 2011-10-04 | ヘルパーｔ細胞の活性化方法 |
| JP2016109398A Active JP6298101B2 (ja) | 2010-10-05 | 2016-05-31 | ヘルパーｔ細胞の活性化方法 |
| JP2017237964A Pending JP2018093870A (ja) | 2010-10-05 | 2017-12-12 | ヘルパーｔ細胞の活性化方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537718A Active JP6134139B2 (ja) | 2010-10-05 | 2011-10-04 | ヘルパーｔ細胞の活性化方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017237964A Pending JP2018093870A (ja) | 2010-10-05 | 2017-12-12 | ヘルパーｔ細胞の活性化方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10654892B2 (OSRAM) |
| EP (1) | EP2626418B8 (OSRAM) |
| JP (3) | JP6134139B2 (OSRAM) |
| KR (3) | KR20140009168A (OSRAM) |
| CN (2) | CN103298928B (OSRAM) |
| AR (1) | AR083295A1 (OSRAM) |
| AU (1) | AU2011313327B2 (OSRAM) |
| BR (1) | BR112013008230A2 (OSRAM) |
| CA (1) | CA2813557C (OSRAM) |
| CO (1) | CO6710946A2 (OSRAM) |
| EA (1) | EA037547B1 (OSRAM) |
| ES (1) | ES2849187T3 (OSRAM) |
| IL (2) | IL225536B (OSRAM) |
| MX (2) | MX361299B (OSRAM) |
| MY (1) | MY170306A (OSRAM) |
| NZ (2) | NZ703560A (OSRAM) |
| PH (1) | PH12013500654A1 (OSRAM) |
| SG (3) | SG189287A1 (OSRAM) |
| TW (2) | TWI608099B (OSRAM) |
| WO (1) | WO2012046730A1 (OSRAM) |
| ZA (1) | ZA201303056B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2071028T3 (pl) | 2003-11-05 | 2012-06-29 | Int Inst Cancer Immunology Inc | Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR |
| EP2565201B1 (en) | 2005-10-17 | 2014-11-26 | Sloan-Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
| EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
| ES2559062T3 (es) | 2007-02-27 | 2016-02-10 | International Institute Of Cancer Immunology, Inc. | Método para la activación de linfocitos T colaboradores y composición para su uso en el método |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| AR083295A1 (es) * | 2010-10-05 | 2013-02-13 | Univ Osaka | Metodo para activar celulas t auxiliares |
| AU2013207669C1 (en) | 2012-01-13 | 2018-05-31 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| KR20150046346A (ko) * | 2012-09-12 | 2015-04-29 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 항원 특이적 헬퍼 t 세포 리셉터 유전자 |
| KR102158225B1 (ko) * | 2012-12-17 | 2020-09-21 | 오츠카 세이야쿠 가부시키가이샤 | 헬퍼 t세포의 활성화 방법 |
| PT2945647T (pt) | 2013-01-15 | 2020-11-26 | Memorial Sloan Kettering Cancer Center | Péptidos imunogénicos wt-1 e métodos de uso dos mesmos |
| US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
| WO2014157692A1 (ja) | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドコンジュゲートワクチン |
| EP3112378B1 (en) * | 2014-02-26 | 2020-06-24 | Tella, Inc. | Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide |
| CN107427581A (zh) | 2014-12-25 | 2017-12-01 | 株式会社癌免疫研究所 | T细胞群的改变方法 |
| CN106565836B (zh) * | 2015-10-10 | 2020-08-18 | 中国科学院广州生物医药与健康研究院 | 高亲和力的可溶性pdl-1分子 |
| WO2018088439A1 (ja) | 2016-11-09 | 2018-05-17 | 国立大学法人大阪大学 | Ｔ細胞集団の改変方法 |
| EP3549957A4 (en) * | 2016-11-30 | 2020-08-05 | Sumitomo Dainippon Pharma Co., Ltd. | AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER |
| CN111741972A (zh) * | 2017-12-27 | 2020-10-02 | 大日本住友制药株式会社 | Wt1衍生肽的缀合物和包含其的组合物 |
| CN112812153B (zh) * | 2018-02-15 | 2022-06-14 | 国立大学法人旭川医科大学 | 癌症抗原肽 |
| JP2021534752A (ja) * | 2018-08-22 | 2021-12-16 | フレッド ハッチンソン キャンサー リサーチ センター | Ｋｒａｓ抗原またはｈｅｒ２抗原を標的とする免疫療法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5726288A (en) | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
| PT1103564E (pt) | 1998-07-31 | 2009-03-13 | Int Inst Cancer Immunology Inc | Antigénios de cancro com base no produto do gene supressor de tumor wt1 |
| US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
| BR9914116A (pt) | 1998-09-30 | 2002-01-15 | Corixa Corp | Composições e métodos para imunoterapia especìfica de wt1 |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| CA2401070A1 (en) | 2000-02-22 | 2001-08-30 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
| US20040097703A1 (en) | 2001-03-22 | 2004-05-20 | Haruo Sugiyama | Wt1 modified peptide |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| ATE494905T1 (de) | 2001-06-29 | 2011-01-15 | Chugai Pharmaceutical Co Ltd | Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom |
| JPWO2003028758A1 (ja) | 2001-09-28 | 2005-01-13 | 治夫 杉山 | 抗原特異的ｔ細胞の誘導方法 |
| WO2003028757A1 (en) | 2001-09-28 | 2003-04-10 | Haruo Sugiyama | Novel method of inducing antigen-specific t cells |
| JP4365784B2 (ja) | 2002-06-12 | 2009-11-18 | 株式会社癌免疫研究所 | Ｈｌａ−ａ２４拘束性癌抗原ペプチド |
| WO2004024175A1 (ja) | 2002-09-12 | 2004-03-25 | Haruo Sugiyama | 癌抗原ペプチド製剤 |
| EP1548028B1 (en) | 2002-09-20 | 2009-09-09 | International Institute of Cancer Immunology, Inc. | Substituted type peptides of wt1 |
| ES2332590T3 (es) | 2003-01-15 | 2010-02-09 | International Institute Of Cancer Immunology, Inc. | Dimero peptidico. |
| KR101431312B1 (ko) | 2003-06-27 | 2014-08-20 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Ｗｔ1 백신 적응 환자의 선택 방법 |
| PL2071028T3 (pl) | 2003-11-05 | 2012-06-29 | Int Inst Cancer Immunology Inc | Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR |
| EP2186896B1 (en) | 2004-03-31 | 2015-11-04 | International Institute of Cancer Immunology, Inc. | Cancer antigen peptides derived from WT1 |
| US7608769B2 (en) * | 2004-05-12 | 2009-10-27 | First Act, Inc. | Packaged drum set |
| JP4719876B2 (ja) | 2005-04-04 | 2011-07-06 | 国立大学法人愛媛大学 | Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド |
| EP2565201B1 (en) | 2005-10-17 | 2014-11-26 | Sloan-Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
| RU2424247C2 (ru) | 2005-11-30 | 2011-07-20 | Интернэшнл Инститьют Оф Кэнсер Иммьюнолоджи, Инк. | Пептид, индуцирующий цитотоксические т-клетки (цтл), способ индукции цтл, антитело, связывающееся с этим пептидом, применение пептида в фармацевтической композиции и для лечения или предупреждения рака, антигенпредставляющая клетка |
| US7420880B2 (en) | 2005-12-29 | 2008-09-02 | Timex Group B.V. | Multimode electronic device with calibrating/setting mechanism |
| DK2518149T3 (en) | 2006-02-22 | 2016-01-11 | Int Inst Cancer Immunology Inc | HLA-A * 3303-LIMITED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
| EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
| CN101573448B (zh) * | 2006-12-28 | 2012-07-11 | 株式会社癌免疫研究所 | Hla-a*1101限制的wt1肽及含有其的药物组合物 |
| ES2559062T3 (es) | 2007-02-27 | 2016-02-10 | International Institute Of Cancer Immunology, Inc. | Método para la activación de linfocitos T colaboradores y composición para su uso en el método |
| KR101669279B1 (ko) | 2007-03-05 | 2016-10-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| AR083295A1 (es) * | 2010-10-05 | 2013-02-13 | Univ Osaka | Metodo para activar celulas t auxiliares |
| KR102158225B1 (ko) | 2012-12-17 | 2020-09-21 | 오츠카 세이야쿠 가부시키가이샤 | 헬퍼 t세포의 활성화 방법 |
-
2011
- 2011-10-04 AR ARP110103676A patent/AR083295A1/es unknown
- 2011-10-04 BR BR112013008230A patent/BR112013008230A2/pt not_active Application Discontinuation
- 2011-10-04 SG SG2013025622A patent/SG189287A1/en unknown
- 2011-10-04 JP JP2012537718A patent/JP6134139B2/ja active Active
- 2011-10-04 MY MYPI2013001197A patent/MY170306A/en unknown
- 2011-10-04 TW TW100135857A patent/TWI608099B/zh active
- 2011-10-04 CN CN201180058552.2A patent/CN103298928B/zh active Active
- 2011-10-04 NZ NZ703560A patent/NZ703560A/en unknown
- 2011-10-04 ES ES11830662T patent/ES2849187T3/es active Active
- 2011-10-04 TW TW105107752A patent/TW201623616A/zh unknown
- 2011-10-04 NZ NZ609460A patent/NZ609460A/en unknown
- 2011-10-04 WO PCT/JP2011/072874 patent/WO2012046730A1/ja not_active Ceased
- 2011-10-04 CN CN201610191489.4A patent/CN105802910A/zh active Pending
- 2011-10-04 CA CA2813557A patent/CA2813557C/en active Active
- 2011-10-04 KR KR1020137011554A patent/KR20140009168A/ko not_active Ceased
- 2011-10-04 SG SG10202108581TA patent/SG10202108581TA/en unknown
- 2011-10-04 PH PH1/2013/500654A patent/PH12013500654A1/en unknown
- 2011-10-04 KR KR1020207004213A patent/KR102171794B1/ko active Active
- 2011-10-04 MX MX2013003884A patent/MX361299B/es active IP Right Grant
- 2011-10-04 SG SG10201508252PA patent/SG10201508252PA/en unknown
- 2011-10-04 AU AU2011313327A patent/AU2011313327B2/en active Active
- 2011-10-04 US US13/877,768 patent/US10654892B2/en active Active
- 2011-10-04 KR KR1020197008457A patent/KR102079480B1/ko not_active Expired - Fee Related
- 2011-10-04 EA EA201390509A patent/EA037547B1/ru unknown
- 2011-10-04 EP EP11830662.0A patent/EP2626418B8/en active Active
-
2013
- 2013-04-02 IL IL225536A patent/IL225536B/en not_active IP Right Cessation
- 2013-04-05 MX MX2018008436A patent/MX2018008436A/es unknown
- 2013-04-25 ZA ZA2013/03056A patent/ZA201303056B/en unknown
- 2013-05-03 CO CO13111246A patent/CO6710946A2/es unknown
-
2016
- 2016-05-03 IL IL245440A patent/IL245440A0/en unknown
- 2016-05-31 JP JP2016109398A patent/JP6298101B2/ja active Active
-
2017
- 2017-12-12 JP JP2017237964A patent/JP2018093870A/ja active Pending
-
2020
- 2020-03-31 US US16/835,761 patent/US12415833B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017006120A5 (OSRAM) | ||
| FI3694529T3 (fi) | Trispesifiset proteiinit ja niiden käyttömenetelmät | |
| JP2017528117A5 (OSRAM) | ||
| JP2019508013A5 (OSRAM) | ||
| JP2013172743A5 (OSRAM) | ||
| JP2018534950A5 (OSRAM) | ||
| JP2017501130A5 (OSRAM) | ||
| EA201590986A1 (ru) | Антитела к ceacam5 и их применения | |
| JP2015522576A5 (OSRAM) | ||
| JP2015134796A5 (OSRAM) | ||
| JP2017501129A5 (OSRAM) | ||
| JP2016535009A5 (OSRAM) | ||
| EP3533877A3 (de) | Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark | |
| JPWO2019107530A5 (OSRAM) | ||
| JPWO2019156137A5 (OSRAM) | ||
| JP2016531927A5 (OSRAM) | ||
| JP2019501141A5 (OSRAM) | ||
| JP2015520178A5 (OSRAM) | ||
| CY1117872T1 (el) | Ολιγοπεπτιδικες ενωσεις και χρησεις εξ' aυτων | |
| JP2012115277A5 (OSRAM) | ||
| JP2012529293A5 (OSRAM) | ||
| JP2012505657A5 (OSRAM) | ||
| JP2019517790A5 (OSRAM) | ||
| JP2019534884A5 (OSRAM) | ||
| JP2017514800A5 (OSRAM) |